[{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Children's Discovery Institute | Polaris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginase||L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginase||L-arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginase||L-arginine","graph1":"Oncology","graph2":"Phase I","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Erkim","sponsor":"Polaris Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Enzyme","year":"2025","type":"Agreement","leadProduct":"Pegargiminase","moa":"||L-arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erkim \/ Polaris Group","highestDevelopmentStatusID":"9","companyTruncated":"Erkim \/ Polaris Group"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"||L-arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Global Coalition for Adaptive Research \/ Polaris Group","highestDevelopmentStatusID":"9","companyTruncated":"Global Coalition for Adaptive Research \/ Polaris Group"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"||L-arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaris Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Undisclosed"},{"orgOrder":0,"company":"Ludwig Institute for Cancer Research","sponsor":"Memorial Sloan Kettering Cancer Center | Duke University | St. Bartholomew's Hospital | Krankenhaus Nordwest | Saint-Luc University Hospital | National Taiwan University Hospital | National Cheng-Kung University Hospital | Chang Gung Memorial Hospital | A","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase II","graph3":"Ludwig Institute for Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Institute for Cancer Research \/ Memorial Sloan Kettering Cancer Center | Duke University | St. Bartholomew's Hospital | Krankenhaus Nordwest | Saint-Luc University Hospital | National Taiwan University Hospital | National Cheng-Kung University Hospital | Chang Gung Memorial Hospital | A","highestDevelopmentStatusID":"8","companyTruncated":"Ludwig Institute for Cancer Research \/ Memorial Sloan Kettering Cancer Center | Duke University | St. Bartholomew's Hospital | Krankenhaus Nordwest | Saint-Luc University Hospital | National Taiwan University Hospital | National Cheng-Kung University Hospital | Chang Gung Memorial Hospital | A"}]
Find Clinical Drug Pipeline Developments & Deals for Pegargiminase
Details :
Under the agreement, Polaris will holds the rights for commercialization of ADI-PEG 20 (pegargiminase). It is being evaluated in late-satge for the treatment of malignant pleural mesothelioma
Details :
ADI-PEG 20 (pegargiminase) is an Arginine Degrader Enzyme drug candidate, which is currently being evaluating clinical trial studies with patients for the treatment of Leiomyosarcoma.
Details :
ADI-PEG 20 (pegylated arginine deiminase, pegargiminase) is designed to deplete the external supply of arginine, and is being investigated for Non-Alcoholic Steatohepatitis (NASH).
Details :
ADI-PEG 20 (pegargiminase) ia arginie degrader, which is being evaluated in phase 2/3 clinical trials in combination with cisplatin & pemetrexed for the treatment of malignant pleural mesothelioma.
Details :
ADI-PEG 20 (pegargiminase) is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed, which is investigated for glioblastoma.
Details :
ADI-PEG 20 is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Details :
ADI-PEG 20 is a Enzyme drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Reset All
